GSK
1,043 hedge funds and large institutions have $20.7B invested in GSK in 2026 Q1 according to their latest regulatory filings, with 125 funds opening new positions, 315 increasing their positions, 380 reducing their positions, and 83 closing their positions.
63% more call options, than puts
Call options by funds: $222M | Put options by funds: $137M
51% more first-time investments, than exits
New positions opened: 125 | Existing positions closed: 83
36% more funds holding in top 10
Funds holding in top 10: 11 → 15 (+4)
4% more funds holding
Funds holding: 1,005 → 1,043 (+38)
1% less ownership
Funds ownership: 19.72% → 18.71% (-1%)
17% less repeat investments, than reductions
Existing positions increased: 315 | Existing positions reduced: 380
41% less capital inflows, than outflows
Capital inflows: $1.65B | Capital outflows: $2.79B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$282M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$154M |
| 3 |
Goldman Sachs
New York
|
+$127M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$111M |
| 5 |
BlackRock
New York
|
+$94.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$534M |
| 2 |
JTC Employer Solutions Trustee
St Helier,
Jersey
|
-$292M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$227M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$145M |
| 5 |
Holocene Advisors
New York
|
-$141M |
GSK Hedge Fund Activity: Q1 2026 in Review
1,043 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2026, worth a combined $20.7B — up 5.9% from $19.5B a quarter earlier.
Buyers outnumbered sellers: 125 funds opened new GSK positions and 83 closed out — a net gain of 42 holders — while 315 added to existing stakes and 380 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $282M. The largest seller was Dodge & Cox, cutting an estimated $534M.
- 1,043 institutional investors held GSK (GSK) as of Q1 2026, up from 1,005 in Q4 2025.
- Funds reported $20.7B of GSK stock for Q1 2026, up 5.9% quarter-over-quarter.
- 125 funds opened new GSK positions in Q1 2026 and 83 closed out, a net change of +42 holders.
- The largest GSK buyer in Q1 2026 was Morgan Stanley, an estimated $282M added.
- The largest GSK seller in Q1 2026 was Dodge & Cox, an estimated $534M sold.
Based on aggregated 13F filings for Q1 2026.